Introduction
The HER-2/neu (also known as c-erbB-2) oncogene encodes a molecular weight of 185 000 dalton epidermal growth factor (EGF) receptor-related transmembrane protein (p185) with intrinsic tyrosine kinase activity (Coussens et al., 1985; Bargmann et al., 1986; Yamamoto et al., 1986) . The normal human HER-2/ neu proto-oncogene is frequently ampli®ed or overexpressed in many types of human cancers. HER-2/neu overexpression correlates with tumor grade, size, relapse rate, lymph node and visceral metastases in breast cancer patients and decreased disease-free survival in breast, ovary, lung, stomach and salivary gland cancers (Slamon et al., 1987; Borg et al., 1990; Paterson et al., 1991; Kallioniemi et al., 1991; Press et al., 1993 Press et al., , 1994 Berchuck et al., 1990; Kern et al., 1990; Yonemura et al., 1991) . Transgenic mice carrying mutation-activated HER-2/neu, or overexpressing normal HER-2/neu, induce mammary adenocarinoma with a high frequency of metastasis (Muller et al., 1988; Bouchard et al., 1989; Guy et al., 1992) . Our previous experiments have also demonstrated that expression of activated rat HER-2/neu or overexpression of normal HER-2/neu can induce experimental metastasis in mouse 3T3 cells and human lung cancer cells respectively (Yu et al., , 1994 . More recently, HER-2/neu overexpression has also been shown to induce chemoresistance (Tsai et al., 1993 (Tsai et al., , 1995 . Taken together, these results indicate that HER-2/neu is a potent oncogene that contributes to the malignancy of human tumors.
We have previously reported that the adenovirus 5 E1A gene product repressed HER-2/neu oncogene overexpression through the HER-2/neu gene promoter and suppressed the tumorigenic and metastatic potential of activated rat HER-2/neu oncogenetransformed mouse 3T3 cells (Yu et al., 1990 (Yu et al., , 1992 (Yu et al., , 1993 Yan et al., 1991) . Recently, using either adenovirus or cationic liposome delivery system, we have also demonstrated signi®cant therapeutic eects of E1A in nude mice carrying HER-2/neu-overexpressing ovarian and lung cancers Yu et al., 1995; Hung et al., 1995; Chang et al., 1996) . Since HER-2/neu overexpression is also frequently found in breast cancer in addition to ovarian and lung cancers, and the routes of treatment for dierent cancer types could be quite distinct, we have established an orthotopic breast cancer model and examined E1A anti-tumor activity in this animal model.
Results

Transduction eciency of lacZ gene delivered by adenoviral vector in vitro
To optimize the infection conditions for E1A gene delivery, we ®rst transduced breast cancer cell lines with Ad.RSVlacZ, a recombinant replication-de®cient adenovirus expressing lacZ gene (see Materials and methods), with viral stocks at dierent virus/tumor cell (V/T) ratios. Two days later, the cells were ®xed and stained with X-gal. Thus, cells expressing the lacZ gene turned blue and provided a convenient way to calculate virus transduction eciency. The transduction efficiencies of SKBR-3 and MDA-MB-361 cells, which overexpress HER-2/neu were very high: 75% to 85% can be transduced at V/T ratios of 20 : 1 after a single cycle of infection ( Figure 1A ). The infection eciencies of MDA-MB-231 and MDA-MB-435, which do not overexpress HER-2/neu, were lower, i.e., 30 ± 50% after a single exposure at a V/T ratio of 50 : 1 ( Figure 1A) . However, the transduction eciency can be increased to 60 ± 70% at a V/T ratio of 50 : 1 after two exposure periods ( Figure 1B) . To obtain the maximum eciency with lesser side eects, we used a single exposure at the V/T ratio of 20 : 1 for HER-2/neu-overexpressing cells, or a two-time exposure at a V/T ratio of 50 : 1 for HER-2/neu low expressing cells as the optimal therapeutic doses in later experiments in vitro.
Inhibition of cell growth in HER-2/neu-overexpressing cell lines
To examine whether infection of Ad.E1A(+), a replication-de®cient adenovirus expressing E1A (see Materials and methods), could suppress cell growth in vitro, HER-2/neu-overexpressing MDA-MB-361 and SKBR-3 cells were infected once with Ad.E1A(+) at a V/T ratio of 20 : 1; cell number was then counted for 7 consecutive days. Ad.E1A(+) suppressed cell growth compared with either Ad.E1A(7) or PBS (Figure 2A and B). Our previous results already showed that expression of HER-2/neu p185 was inhibited by Ad.E1A(+) transduction in vitro at a V/T ratio of 20 : 1 in MDA-MB-361 and SKBR-3 cells (Yan et al., 1991) . However, Ad.E1A(+) could not inhibit the cell growth of HER-2/neu low expressing cell lines MDA-MB-231 and MDA-MB-435, even after two-time infection at a V/T ratio of 50 : 1 ( Figure 2C and D).
Tumor development and mouse survival after E1A transduction
We have previously shown that both adenovirus-and cationic liposome-delivery systems successfully transferred E1A gene into tumor cells and suppressed tumor development in an orthotopic ovarian cancer model through i.p. treatment Yu et al., 1995) . To examine whether E1A tumor suppressor function can be extended to a breast cancer model, and compare the therapeutic ecacy between these two delivery systems in a dierent route of treatment, we used both adenovirus-and cationic liposome-mediated gene transfer to transduce E1A into a mammary fat pad breast cancer model. In the previous reports, we showed eective tumor suppression in an ovarian cancer model by 10 8 PFU/mouse weekly injection for multiple adenovirus administration, or 15 mg DNA liposome complex/mouse weekly injection for liposome administration Yu et al., 1995) . So, we chose these conditions for the present experiments.
MDA-MB-361 cells (5610 6 ) cells were transplanted to each mammary fat pad. Then 1.5 months later, when the solid tumor became palpable, the mice were treated locally with either adenovirus or liposome-E1A for 6 months. Then, mice were either sacri®ced for detection of metastasis after treatment was stopped for 2 months, or continually observed for survival up to 2 years. More than 80% of mice treated with either PBS, 5 cells/well in 6-well plates were infected once a day for 1 ± 4 days with Ad.RSVlacZ at V/T ratio of 50 : 1; 2 days after the ®nal infection, cells were stained and evaluated for infection eciency as described above Ad.E1A(7), or a liposome-E1A frame-shift mutant continued to develop tumors and eventually died of tumors between 8 ± 15 months. However, only 20% of mice treated with Ad.E1A(+) and 40% of mice treated with liposome-E1A continued to develop tumors and died between 14 ± 16 months; the rest remained tumorfree for up to 2 years ( Figure 3A) . Also, the tumor nodules from the E1A-treated mice were smaller than those of control mice (P50.05) and no E1A-treated mice were detected to contain metastatic tumors in other organs ( Figure 3B ; Table 1 ). We observed no signi®cant side eects (i.e. weight loss or change in behavior of mice) in our multiple injection strategy at the current viral and liposome doses. The median survivals for Ad.E1A(+)-treated, liposome-E1A-treated, control Ad.E1A(7)-treated, control liposome-E1A-mutant-treated and control PBS-treated mice were 42 years, 42 years, 12.3 months, 14 months, and 9.7 months, respectively (Table 1) . Our statistical analysis, using log-rank and Gehan-Breslow test showed a signi®cant dierence in survival between the E1A-treated and control mice (P50.05). The therapeutic ecacy of adenovirus-mediated E1A delivery was slightly better than that of liposome-mediated E1A delivery.
Expression of E1A protein and suppression of HER-2/ neu p185 in vivo
To investigate whether the therapeutic eects on tumors in vivo were due to E1A expression, expression of the transduced E1A gene in tumors from one mouse in each group were analysed by Western blot. E1A gene expression was detected in E1A-treated MDA-MB-361 tumor cells by Western blot (Figure 4 ). E1A expression in the Ad.E1A(+)-treated mouse was three times higher than in the liposome-E1A-treated mouse. In comparison, no E1A gene expression was detectable in Ad.E1A(7)-treated, liposome-E1A-mutant-treated, or PBS-treated mice as expected. To con®rm whether p185 expression was repressed in the E1A-treated tumor cells, we also performed immunohistochemical staining using a polyclonal antibody against p185. The result revealed dramatically reduced p185 expression in about 50% of Ad.E1A(+)-treated cells and 35% of liposome-E1A-treated cells. A representative area of low p185 expression can be seen in Figure 5B shown), Ad.E1A(7) or liposome-E1A-mutant ( Figure  5A and C) stained positive for p185.
Distribution of adenovirus-or liposome-mediated gene transfer in vivo
An ideal therapeutic approach to cancer gene therapy should eciently target tumor cells without interfering with the normal function of other organs in vivo. Therefore, we studied the localization of gene expression in the tumor versus normal organs by either adenovirus or liposome delivery system through local injection. The lacZ gene expression in MDA-MB-361 breast cancers in mammary fat pad was evaluated by b-gal staining 3 days after mammary fat pad administration of 10 8 PFU Ad.RSVlacZ (once), liposome-RSVlacZ (15 mg/mouse, one injection/day for 3 consecutive days); Ad.E1A(7) or liposome-E1A-mutant was used as negative controls. Strong bgal staining was detected in tumors with virtually no detectable b-gal activity in normal tissues such as liver, lung, kidney, intestine, heart and spleen as compared to controls. Tissue sections stained with X-gal further showed intracellular b-gal activity in tumor tissues injected with Ad.RSVlacZ ws stronger than those injected with liposome-pHC/lacZ (3
. These results indicate that speci®c tumor targeting could be achieved by local administration of adenovirus or liposome containing a reporter gene and expression level of gene delivered by adenoviral vector in individual cells was signi®cantly higher than that by liposome.
Discussion
We have studied the therapeutic eects of E1A in HER-2/neu-overexpressing breast cancer cells by analysing several dierent biological properties of cancer cells including cell growth in vitro, tumor suppression in vivo, and mouse survival. The results showed that E1A inhibited cell growth in vitro in HER-2/neu-overexpressing cancer cell lines MDA-MB-361 and SKBR-3 but not in HER-2/neu low expressing cancer cell lines, MDA-MB-231 and MDA-MB-435. ) were injected into mammary fat pad in female nu/nu mice (n=10). 1.5 months later, when the palpable solid tumors were detected, the mice were given a local injection of either 0.2 ml of viral solution (5610 8 PFU/ml) or liposome-DNA complexes once a day for 3 consecutive days, then once a week for 6 months. The tumor volume was monitored monthly for 6 months. Then, after the treatment was stopped for 2 months, ®ve mice bearing MDA-MB-361 were sacri®ced to detect metastasis; others were observed for survival for up to 2 years. (B) Tumor growth in mice bearing HER-2/neu-overexpressing breast cancer (n=10 These data suggest that the inhibition of cell growth in vitro by E1A may be through HER-2/neu repression. E1A behaved as a tumor suppressor for HER-2/neuoverexpressing breast cancer cells in the orthotopic breast cancer model. In mice bearing HER-2/neuoverexpressing MDA-MB-361 breast cancer cells, E1A signi®cantly reduced cancer growth and prolonged survival for up to 2 years in 60 ± 80% mice. Western blot analysis showed that E1A was expressed; and immunohistochemical staining indicated that HER-2/neu was suppressed in 50% and 35% of tumor sections treated by adenovirus-or liposome-mediated E1A delivery, respectively. It is worth mentioning that the number of mice with distant metastases was signi®cantly reduced even though a local treatment protocol by mammary fat pad injection was used in the orthotopic breast cancer model (Table 1) . It has been reported that E1A induces sensitivity of p53-dependent and -independent programmed cell death (apoptosis) (Teodoro et al., 1995; Lowe et al., 1993; Rao et al., 1992) . To test whether apoptosis contributes to E1A therapeutic eects in HER-2/neuoverexpressing breast cancer cells, we stained the E1A-treated cancer cells using Tunnel assay. We did detect many apoptotic MDA-MB-361 cells in tissue culture (without serum starvation) after Ad.E1A(+) transduction. However, this did not happen in Ad.E1A(+)-treated either HER-2/neu-overexpressing SKBR-3 cells, or HER-2/neu low expressing MDA-MB-231 and MDA-MB-435 in cell culture, implying additional genetic background might be required for E1A-mediated apoptosis. Since p53 is either deleted (MDA-MB-361) or mutated (SKBR-3, MDA-MB-231, MDA-MB-435) in cell lines tested, apoptosis detected in MDA-MB-361 in vitro should be through p53-independent pathway. We used same procedure to detect apoptosis in tumor tissue obtained from E1A-treated mice, however, there was no signi®cant increase of apoptotic MDA-MB-361 cells. The reason could be due to the fact that E1A-mediated apoptotic cells were quickly degraded in vivo and therefore dicult to be detected as the tumor was removed from mouse 1 week after E1A treatment.
Technically, it is dicult to achieve 100% transduction eciency in vivo especially in liposome-mediated gene delivery. However, impressive therapeutic eects were observed in our breast cancer animal model using liposome-mediated E1A therapy. It is not clear yet whether other mechanisms such as bystander eect might be involved in E1A-mediated cancer therapy. The experiment addressing this issue is currently ongoing in our laboratory. Taken together, we conclude that E1A can function as an eective tumor suppressor in the breast cancer model through local treatment.
We have compared the therapeutic ecacy between adenovirus and liposome E1A delivery systems. In the conditions we chose, the gene expression of adenovirus-mediated system was higher than that of the liposome-mediated system (Figure 4) . However, both delivery systems can achieve reasonable eciency and great therapeutic eects in vivo. It is known that adenovirus can induce immunological response and in¯ammation reactions in immunocompetent animal and human (Simon et al., 1993; Knowles et al., 1995) . On the contrary, the cationic liposome-DNA complex has been shown to be non-immunogenic and have minimal toxic eects (Parker et al., 1995; Nabel et al., 1993) . The issue regarding potential side eects is particularly important in the current protocol, because repeated injections are required. Considering the potentially low toxicity of the liposome-DNA complex, it may still be a better choice even though its therapeutic ecacy is slightly lower than that of Ad.E1A(+). However, we have chosen only one dose in each delivery system to examine therapeutic ecacy in the current study. It may be possible to identify another optimal condition by systematically changing the dose of the two delivery systems and comparing their therapeutic ecacies. We also observed that adenovirus infected HER-2/neu-overexpressing breast cancer cells more eciently than HER-2/neu low expressing breast cancer cells. Although the exact reason is not clear, one possible mechanism could be due to dierent growth rate between these two groups of breast cancer cells. As in general, HER-2/neuoverexpressing breast cancer cells grow more slowly than HER-2/neu low expressing breast cancer cells.
Breast cancer is one of the most common malignancies in women and accounts for 27% of their cancers in developed countries (Harris et al., 1993) . Ampli®cation or overexpression of HER-2/neu has been found in tumors in 30% of breast cancer patients and correlates with signi®cantly shorter survival ( , 1993) . Therefore, HER-2/neu overexpression may provide an excellent target to develop novel therapeutic strategies for breast cancer patients. Indeed, a monoclonal antibody against HER-2/neu p185 protein has recently been tested in a phase II clinical trial for HER-2/neu-overexpressing metastatic breast cancer patients in which 11.6% overall response rate was achieved (Baselga et al., 1996) . These results are certainly encouraging and indicate that HER-2/neutargeting is a promising way to develop therapeutic strategies. However, the current response rate is far from perfect and there is much room for improvement in therapeutic ecacy. Our E1A gene therapy protocol provides a 60 ± 80% survival rate in the breast cancer animal model. It remains to be seen whether the high therapeutic ecacy from animal experiments could be extended to humans in clinical trials in the future. 
Adenoviral vectors, transduction eciency, and stability in vitro
Recombinant, replication-de®cient adenoviral vectors were prepared by superinfection of 293 cells, puri®ed, titered by plaque assay, and stored in 10% glycerol PBS at 7708C. Plaque assay: 293 cell was grown and reached con¯uence in 60 mm dish. The media was removed and 2 ml series diluted adenovirus in PBS was added and incubated at 378C for 30 min. After that, 0.5% agarose in DMEM media was gently added in the dish. The plaque was counted about 1 week later. Three vectors were used: Ad.E1A(+), an adenovirus type 5 containing E1A but lacking E1B and E3; control vector Ad.E1A (7), which is virtually the same as Ad.E1A(+) but with an additional E1A deletion ; and Ad.RSVlacZ, an adenovirus type 5-based vector lacking E1A, E1B, E3 and containing the rouse sarcoma virus long terminal repeat as a promoter driving the E. coli lacZ gene which codes for the b-gal protein . Cells (2.5610 5 well) in 6-well plates were infected once by Ad.RSVlacZ at dierent virus/tumor cell (V/T) ratios or multiply infected (once/day) at the same ratio. Two days after the ®nal injection, cells were ®xed with 2% formaldehyde, 0.2% gluteraldehyde in PBS at 48C for 5 min and then stained with 1 mg/ml X-gal in 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 2 mM MgCl 2 in PBS at 378C overnight. Infection eciency equaled the no. of positive cells/no. of total cells 6100%. To evaluate the stability of transduced genes in tumor cells, Ad.RSVlacZ transduced cells were grown in 6-well plates for 1 week and then stained with X-gal.
Preparation of liposome-DNA complexes
DC-Chol liposomes were prepared at a 3 : 2 molar ratio of the cationic liposome, 3b [N-(N',N'Dimethyl-ami-no)ethanecarbamoyl]-cholesterol (DC-Chol) and the neutral phospholipid, dioleoylphosphatidylethanolamine (DOPE) as previously described (Gao and Huang, 1991) . Liposome-DNA complexes were formed by gradually adding DNAs to liposome in serum-free medium at liposome (nmol)/DNA (mg) ratio of 13 : 1, and incubated at 378C for 10 min. Plasmid pE1A expresses only the wild-type genomic E1A region gene of the adenovirus 5. Plasmid E1A frame-shift deletion in the E1A coding sequences (denoted as E1A-mutant in this paper) was used as a control (Hearing and Shenk, 1985) . Plasmid pHC-lacZ expresses the bacterial bgalactosidase (lacZ) marker gene.
In vitro growth rate 
Orthotopic breast cancer model
Female nu/nu mice (n=10) were irradiated with 350 cGy of 60 Co. Then, 5610 6 /mouse of MDA-MB-361 cells were injected into the mammary fat pad of the mice. 1.5 months later, when palpable solid tumors were detected, the mice were given a local injection of either 0.2 ml viral solution (titer, 5610 8 PFU) or liposome-DNA complexes (15 mg DNA: 200 nmol liposome/mouse) once a day for 3 consecutive days and then once a week for 6 months. The tumor volumes were monitored monthly and the cancer metastases and mouse survival rates were observed for up to 2 years.
Immunoblot analysis of adenoviral E1A protein
Protein extracts were prepared from tumor tissues by homogenizing tumor tissue in Laemmli's buer (130 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol). The extracts were boiled for 5 min, cooled in ice, and cleared by centrifuging at 10 000 g for 15 min. The protein concentrations were calculated by bovine serum albumin protein assay. Fifty micrograms of protein was size-fractionated by electrophoresis on a 10% SDS-polyacrylamine gel and then electroblotted onto nitrocellulose membranes. E1A proteins were detected by anti-E1A monoclonal antibody (m58, Pharmingen). Horseradish peroxidase-labeled goat anti-mouse antibody was used as a secondary antibody (Pierce Chemical Co. Rockford, IL). Changes in E1A level were determined by measuring absorbance with a video densitometer (One Scanner using NIH image version 1.57, Macintosh Centris 610 computer).
Immunohistochemical analysis
Histological sections were taken from mice-bearing m.f.p. breast cancer cells (either treated or controls). Frozen sections were ®xed with acetone. The sections were subjected to routine pathological analysis with hematoxylin and eosin staining. Expression of HER-2/neu p185 protein was detected by incubating tissue samples with a rabbit polyclonal antibody against the HER-2/neu oncogene product as primary antibody (DAKO Inc.) and biotinylated goat antibody against rabbit IgG as second antibody, followed by incubation with avidin-biotinperoxidase complex (Vector Labs). Staining was then developed in amino-ethyl carbazole chromogen stock solution (Sigma Chemical Co.). Mayer's hematoxylin was used as a counterstain.
Distribution of adenoviral vector or liposome in vivo after mammary fat pad injection
The female nu/nu mice were initially administered MDA-MB-361 breast cancer cells into the mammary fat pad as described before; then 1.5 months later after tumors developed, 0.2 ml Ad.RSVlacZ (titer: 5610 8 PFU/ml, once) or liposome-pHC-lacZ DNA complex (15 mg DNA: 200 nmol liposome/mouse, one injection/day for 3 consecutive days) was injected locally. Two days later, the tumor tissue or normal tissue was collected and ®xed with 2% formaldehyde, 0.2% gluteraldehyde in PBS at 48C for 5 min, and then stained with 1 mg/ml X-gal. Ad.E1A(7) virus and liposome-E1A-mutant were used as negative controls.
